ABP 980 与参照曲妥珠单抗在 HER2 阳性早期乳腺癌中的疗效与安全性(LILAC 研究):一项随机双盲 3 期试验
LILAC 研究是一项随机双盲 3 期等效性试验,比较 ABP 980(曲妥珠单抗生物类似药)与参照曲妥珠单抗在 HER2 阳性早期乳腺癌新辅助治疗中的疗效与安全性。共 725 例患者随机分配,主要终点为病理完全缓解(pCR)。基于本地实验室评估,ABP 980 组 pCR 为 48%(95% CI 43-53),曲妥珠单抗组为 41%(35-46);中心实验室评估结果均在等效界值内,安全性相似。
要点
- ABP 980 与曲妥珠单抗在新辅助治疗中 pCR 率相似,中心实验室评估符合等效性。
- 基于本地实验室评估,pCR 的风险差和风险比 90% CI 上限超过预设等效界值,等效性结论不明确。
- 两组在新辅助和辅助阶段的安全性相似,3 级及以上不良事件发生率相当。
核心结论
- 基于本地实验室评估,ABP 980 与曲妥珠单抗的 pCR 风险差和风险比 90% CI 下限显示非劣效,但上限超过预设等效界值,等效性结论不确定。
- 基于中心实验室评估的敏感性分析中,两药疗效估计值均在预设等效界值内,提示疗效相似。
- ABP 980 与曲妥珠单抗在新辅助和辅助阶段的安全性相似。
研究设计与样本
- 随机、多中心、双盲、活性对照的等效性试验,在 20 个国家 97 个中心进行。
- 入组 827 例,随机分配 725 例接受 ABP 980(n=364)或曲妥珠单抗(n=361)。
- 主要终点评估人群为 696 例随机分配、接受至少一次新辅助研究产品并接受手术的患者(ABP 980 组 358 例,曲妥珠单抗组 338 例)。
主要发现
- 本地实验室评估:ABP 980 组 pCR 172/358(48%,95% CI 43-53),曲妥珠单抗组 137/338(41%,35-46)。
- 新辅助阶段 3 级及以上不良事件:ABP 980 组 54/364(15%),曲妥珠单抗组 51/361(14%);最常见为中性粒细胞减少,两组各 21 例(6%)。
- 辅助阶段 3 级及以上不良事件:继续 ABP 980 组 30/349(9%),继续曲妥珠单抗组 11/171(6%),曲妥珠单抗换 ABP 980 组 13/171(8%)。
关键数值与推荐
- 主要终点为本地实验室评估的乳腺组织和腋窝淋巴结病理完全缓解。
- 随机分配按 T 分期、淋巴结状态、激素受体状态、计划紫杉醇给药方案和地理区域分层。
临床怎么用
- ABP 980 可作为曲妥珠单抗的生物类似药用于 HER2 阳性早期乳腺癌的新辅助和辅助治疗。
- 临床决策时可参考中心实验室评估结果,两药疗效相似且安全性相当。
- 治疗期间应监测 3 级及以上不良事件,尤其是中性粒细胞减少和感染。
局限性
- 基于本地实验室评估的主要终点未达到预设等效界值,等效性结论不确定。
- 中心实验室评估为敏感性分析,样本量略少于主要分析人群。
- 研究主要在欧洲和南美洲进行,人群代表性可能有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: ABP 980 (Amgen Inc, Thousand Oaks, CA, USA) is a biosimilar of trastuzumab, with analytical, functional, and pharmacokinetic similarities. We compared the clinical safety and efficacy of ABP 980 with that of trastuzumab in women with HER2-positive early breast cancer. METHODS: We did a randomised, multicentre, double-blind, active-controlled equivalence trial at 97 study centres in 20 countries, mainly in Europe and South America. Eligible women were aged 18 years or older, had histologically confirmed HER2-positive invasive early breast cancer, an Eastern Cooperative Oncology Group performance status score of 0 or 1, and were planning to have surgical resection of the breast tumour with sentinel or axillary lymph node dissection and neoadjuvant chemotherapy. After four cycles of run-in anthracycline-based chemotherapy, patients were assigned 1:1 to receive ABP 980 or trastuzumab with a permuted block design (blocks of four) computer-generated randomisation schedule. Patients received neoadjuvant therapy with a loading dose (8 mg/kg) of ABP 980 or trastuzumab plus paclitaxel 175 mg/m2 in a 90 min intravenous infusion, followed by three cycles of 6 mg/kg intravenous ABP 980 or trastuzumab plus paclitaxel 175 mg/m2 every 3 weeks in 30 min intravenous infusions (or 80 mg/m2 paclitaxel once per week for 12 cycles if that was the local standard of care). Randomisation was stratified by T stage, node status, hormone receptor status, planned paclitaxel dosing schedule, and geographical region. Surgery was completed 3-7 weeks after the last dose of neoadjuvant treatment, after which adjuvant treatment with ABP 980 or trastuzumab was given every 3 weeks for up to 1 year after the first dose in the study. Patients had been randomly assigned at baseline to continue APB 980, continue trastuzumab, or switch from trastuzumab to APB 980 as their adjuvant treatment. The co-primary efficacy endpoints were risk difference and risk ratio (RR) of pathological complete response in breast tissue and axillary lymph nodes assessed at a local laboratory in all patients who were randomly assigned and received any amount of neoadjuvant investigational product and underwent surgery. We assessed safety in all patients who were randomly assigned and received any amount of investigational product. This trial is registered with ClinicalTrials.gov, number NCT01901146 and Eudra, number CT 2012-004319-29. FINDINGS: Of 827 patients enrolled, 725 were randomly assigned to receive ABP 980 (n=364) or trastuzumab (n=361). The primary endpoint was assessable in 696 patients (358 who received ABP 980 and 338 who received trastuzumab). Pathological complete response was recorded in 172 (48%, 95% CI 43-53) of 358 patients in the ABP 980 group and 137 (41%, 35-46) of 338 in the trastuzumab group (risk difference 7·3%, 90% CI 1·2-13·4; RR 1·188, 90% CI 1·033-1·366), with the upper bounds of the CIs exceeding the predefined equivalence margins of 13% and 1·318, respectively. Pathological complete response in the central laboratory assessment was seen in 162 (48%) of 339 patients assigned to ABP 980 at baseline and 138 (42%) of 330 assigned to trastuzumab at baseline (risk difference 5·8%, 90% CI -0·5 to 12·0, and RR 1·142, 90% CI 0·993 to 1·312). Grade 3 or worse adverse events during the neoadjuvant phase occurred in 54 (15%) of 364 patients in the ABP 980 group and 51 (14%) of 361 patients in the trastuzumab group, of which the most frequent grade 3 or worse event of interest was neutropenia, occurring in 21 (6%) patients in both groups. In the adjuvant phase, grade 3 or worse adverse events occurred in 30 (9%) of 349 patients continuing ABP 980, 11 (6%) of 171 continuing trastuzumab, and 13 (8%) of 171 who switched from trastuzumab to ABP 980, the most frequent grade 3 or worse events of interest were infections and infestations (four [1%], two [1%], and two [1%]), neutropenia (three [1%], two [1%], and one [1%]), and infusion reactions (two [1%], two [1%], and three [2%]). Two patients died from adverse events judged to be unrelated to the investigational products: one died from pneumonia while receiving neoadjuvant ABP 980 and one died from septic shock while receiving adjuvant ABP 980 after trastuzumab. INTERPRETATION: Although the lower bounds of the 90% CIs for RR and risk difference showed non-inferiority, the upper bounds exceeded the predefined equivalence margins when based on local laboratory review of tumour samples, meaning that non-superiority was non-conclusive. In our sensitivity analyses based on central laboratory evaluation of tumour samples, estimates for the two drugs were contained within the predefined equivalence margins, indicating similar efficacy. ABP 980 and trastuzumab had similar safety outcomes in both the neoadjuvant and adjuvant phases of the study. FUNDING: Amgen.
引用
- von Minckwitz G, Colleoni M, Kolberg HC, et al. Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2018. PMID: 29880292. doi:10.1016/S1470-2045(18)30241-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。